Abstract: Disclosed is a high anticoagulation extracorporeal circulation tube, which include the following preparation methods: S1, firstly, aminating the surface of the tube by extrusion molding; S2, activating heparin groups by a direct coupling method; S3, heparinizing PVC or PC tubes; S4, then, using albumin, functionalized PEG which can react with amino groups, and phosphate to further surface modify the inner wall of heparinized PVC or PC tube to block the sites not modified by heparinization, so as to shield the adsorption of platelets and protein in blood on the inner wall. The application can produce a novel high anticoagulation extracorporeal circulation tube with low price and high biocompatibility, which expands the application in clinic.

Abstract: Disclosed is a high anticoagulation ECMO and extracorporeal circulation consumable, which include the following preparation methods: S1, aminating the surface of ECMO blood circulation device and extracorporeal circulation consumables; S2, activating heparin groups; S3, heparinizing the ECMO blood circulation device and extracorporeal circulation consumables; S4, modification of enhancer. The application can produce a novel high anticoagulation extracorporeal circulation tube with low price and high biocompatibility, which expands the application in clinic.

Abstract: Disclosed is a high anticoagulation extracorporeal circulation tube, which include the following preparation methods: S1, firstly, aminating the surface of the tube by extrusion molding; S2, activating heparin groups by a direct coupling method; S3, heparinizing PVC or PC tubes; S4, then, using albumin, functionalized PEG which can react with amino groups, and phosphate to further surface modify the inner wall of heparinized PVC or PC tube to block the sites not modified by heparinization, so as to shield the adsorption of platelets and protein in blood on the inner wall. The application can produce a novel high anticoagulation extracorporeal circulation tube with low price and high biocompatibility, which expands the application in clinic.

Abstract: The method of preparing polyethyleneimine-lipid nanoparticles (PEI-LNPs) for transfecting stem cells includes the following steps: S1, adding anhydride to a PEI solution to produce polycarboxylic acid; S2, dissolving the PEI-LNPs from S1, together with DPPC, DPPG, DPPE-PEG-COOH and cholesterol in chloroform, dissolving cGAMP in a water and then adding to such chloroform solution, and performing vacuum evaporation to remove the chloroform; S3, adding PBS for hydration, and performing ultrasonication to obtain liposomes; and S4, adding EDC/NHS to the liposome solution obtained for reaction for 15 min, then adding mRNA, and stirring the mixed solution to obtain a bionic virus nanovaccine. The prepared PEI-LNPs are used for delivering an mRNA vaccine and transfecting stem cells, wherein through a lipid PEI derivative library synthesized based on short-branched PEI with a variable length and hydrophobic tail substitution ratio, short-branched PEI can form a stable complex with the mRNA vaccine.

Abstract: An exosome hydrogel for treating severe respiratory diseases is provided and includes a temperature-sensitive hydrogel and an exosome; wherein the temperature-sensitive hydrogel is PLGA-PEG-PLGA. According to the present invention, PLGA-PEG-PLGA generates a hydrogel exosome through a phase transition at a body temperature, and the hydrogel stays in lungs for a longer time than common exosomes, thereby making the exosome remain at an infection site and producing a better therapeutic effect. The exosome hydrogel features high safety, is suitable for promotion, and has good potential in medical treatment.

Abstract: A method for preparing an atomizing SARS-CoV-2 nanovaccine includes the followings steps: mimicking a structure of SARS-COV-2 with receptor binding domains (RBDs) of SARS-COV-2, by taking Poly(I:C) mimicking viral genetic materials as an immunoadjuvant, and electronegative liposomes that enter pulmonary macrophages efficiently as a viral capsid structure; adding a catalyst and an RBD antigen protein to a liposome solution, linking the antigen protein to a liposome surface, and obtaining a bionic virus nanovaccine after purification and freeze-drying treatment. Compared with conventional intramuscular and subcutaneous inoculation, the SARS-CoV-2 vaccine of the present invention features strong mucosal protection effect, high safety, extensive application, and excellent potential.